纽约 - 市值4.79亿美元、专注于脑健康疾病的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)今日宣布任命Matt Wiley为首席商务官 (CCO)。根据InvestingPro数据显示，该公司保持稳健的财务状况，现金多于债务，流动比率达到7.25倍。Wiley加入执行团队后将指导公司潜在产品的商业化战略，包括用于广泛性焦虑障碍 ...

Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

周五，研究机构H.C. Wainwright维持了对专注于开发精神健康疾病治疗方案的临床阶段生物制药公司MindMed（NASDAQ:MNMD）的买入评级和55.00美元的目标价。目前该股交易价格为6.61美元，分析师们认为具有显著上涨空间，他们的目标价区间在16美元至55美元之间。该机构分析师强调，即将到来的三期临床试验结果将成为推动股价达到其目标价的潜在催化剂。根据InvestingPro数据 ...

Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a research note issued on Monday, March 24th. Chardan Capital analyst R. Li ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health ...

(NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company ...

In this article, we are going to take a look at where Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana ...

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event. MindMed is a late-stage clinical ...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company ...